scholarly journals Comorbidity of NAFLD and GERD as a cardiometabolic phenomenon

2021 ◽  
pp. 49-54
Author(s):  
O. V. Khlynova ◽  
K. M. Liu
Keyword(s):  
Preventive Measures ◽  
Work Design ◽  
Newly Diagnosed ◽  
Alcoholic Fatty Liver ◽  
Cardiometabolic Disorders ◽  
Key Characteristics ◽  
Preclinical Diagnosis ◽  
Cardio Vascular ◽  
Alcoholic Fatty Liver Disease

The aim of the study was to study the cardiometabolic characteristics in individuals with an associated course of non-alcoholic fatty liver disease (NAFLD) and gastroesophageal reflux disease (GERD) in comparison with isolated cases of diseases.Materials and methods. The study included 120 patients (30 — with GERD, 30 — with NAFLD, 30 — with GERD + NAFLD. Work design — prospective parallel comparative study with 2 stages. Stage I — inclusion in the study, assessment of the main cardiometabolic, cardio vascular rice (CVR) according to the SCORE scale and the Framingham scale. Stage II — follow-up of the participants for 5 years, re-examination and riskmetry.Results. It has been shown that with a combination of NAFLD and GERD, the pathogenetic mechanisms involved in the formation of NAFLD (especially in steatohepatitis) affect the key characteristics of the metabolic profile and the state of the CV system to a greater extent than GERD. The total CVR values in this category of patients were: 4.8 — SCORE; 13.4 — on the Framingham scale. Over 5 years in this group, 10 (33% of the initial) newly diagnosed cases of CVD were verified: 6 — AH, 3 — IHD, 1 — AH + IHD. CVR for the NAFLD and GERD group increased: according to the SCORE scale — from low risk (4.8) to high (8.9), and according to the Framingham scale, the dynamics was even more negative (from 13.4 to 18.6).Conclusion. Kinds of cardiometabolic disorders in persons with comorbidity of NAFLD and GERD have been proven, which can form the prerequisites for structural cardiovascular changes, including the risks of CVD. This can be a rationale for carrying out additional preventive measures for the groups of patients under discussion, especially in the case of their associated course, as measures for the early preclinical diagnosis of CVR factors and for timely correction of the identified disorders.

scholarly journals Non-resolution of non-alcoholic fatty liver disease (NAFLD) among urban, adult Sri Lankans in the general population: A prospective, cohort follow-up study

PLoS ONE ◽  
2019 ◽  
Vol 14 (10) ◽  
pp. e0224474
Author(s):  
Madunil Anuk Niriella ◽  
Anuradhani Kasturiratna ◽  
Thulani Beddage ◽  
Dileepa Senajith Ediriweera ◽  
Shamila Thivanshi De Silva ◽  
...  
Keyword(s):  
Liver Disease ◽  
General Population ◽  
Fatty Liver ◽  
Prospective Cohort ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Follow Up Study ◽  
Alcoholic Fatty Liver Disease

scholarly journals Real-world comorbidities and treatment patterns among patients with non-alcoholic fatty liver disease receiving phosphatidylcholine as adjunctive therapy in Russia

2019 ◽  
Vol 6 (1) ◽  
pp. e000307 ◽  
Author(s):  
Igor V Maev ◽  
Aleksey A Samsonov ◽  
Liudmila K Palgova ◽  
Chavdar S Pavlov ◽  
Elena Shirokova ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Diabetic Patients ◽  
Newly Diagnosed ◽  
Alcoholic Fatty Liver ◽  
Number Of Patients ◽  
Metabolic Comorbidities ◽  
Alcoholic Fatty Liver Disease

ObjectivePrevious research conducted in Russia showed that the number of patients with non-alcoholic fatty liver disease (NAFLD) and associated metabolic comorbidities is large. We conducted an observational study to describe the management of NAFLD in patients with metabolic syndrome in Russia.DesignA total of 2843 adult patients from 174 medical sites across 6 federal districts of Russia with newly diagnosed NAFLD, who had at least one of four comorbidities, namely overweight/obesity, hypertension, type 2 diabetes mellitus, and hypercholesterolaemia, and who received phosphatidylcholine (PPC) as an adjunctive treatment to standard care, were enrolled during 2015–2016.ResultsOverall, 2263 patients (79.6%) had at least two metabolic comorbidities associated with NAFLD; overweight/obesity was the most common comorbidity reported in 2298 patients (80.8%). Simple steatosis was the most frequently identified clinical form of NAFLD, diagnosed in 2128 patients (74.9%). Among hypertensive patients, ACE inhibitors, statins, and sartans were most commonly prescribed. Biguanides were administered in more than half of diabetic patients. In patients with overweight/obesity and hypercholesterolaemia, statins were the most frequently prescribed medications. Almost all patients (2837/2843; 99.8%) were treated with 1.8 g of PPC three times per day. PPC therapy was associated with a 90.5% 6-month compliance rate, high treatment satisfaction, and a favourable safety profile. However, almost 15% of diabetic patients and 40% of overweight/obese patients received no further treatment.ConclusionsIn Russia, patients with newly diagnosed NAFLD represent a population heavily burdened by comorbidities, mainly overweight/obesity and hypercholesterolaemia. A significant part of these patients did not receive a comprehensive pharmacotherapy, highlighting the existing unmet need in the current management of NAFLD patients with metabolic syndrome in Russia.

scholarly journals Non-alcoholic fatty liver disease, cytokeratin-18, and risk of type 2 diabetes mellitus: A cohort study

2019 ◽  
Author(s):  
Ruofan Hu ◽  
Shaoyong Xu ◽  
Han Shen ◽  
Ce Jing ◽  
Aihua Jia ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cohort Study ◽  
Fatty Liver Disease ◽  
Cytokeratin 18 ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Abstract Background & Aims: Although many studies have shown that non-alcoholic fatty liver disease (NAFLD) is associated with type 2 diabetes mellitus (T2DM), no cohort study has explored the relationship between the histopathological grade of NAFLD and the risk of T2DM in NAFLD patients. We aimed to explore whether a higher concentration of cytokeratin-18 (CK-18), as a reliable marker of hepatic fibrosis, was associated with a greater risk of T2DM in patients with NAFLD. Methods: The population-based cohort study was based on China National Diabetes and Metabolic Disorders Survey with a follow-up of five years. NAFLD was determined by ultrasonography. T2DM were diagnosed based on oral glucose tolerance test. Serum CK-8 was measured using the M30 Apoptosense ELISA kit. Results: 457 subjects were enrolled and three groups were analyzed: a non-NAFLD group (n=363), a low-CK-18 NAFLD group (n=46), and a high-CK-18 NAFLD group (n=48). 20 (3.9%) developed diabetes during follow-up. The incidence of T2DM was 2.5%, 8.7%, and 12.5% in the non-NAFLD, low-CK-18 NAFLD, and high-CK-18 NAFLD groups, respectively. Cox proportional hazard regression showed that, compared with the non-NAFLD group, the adjusted relative risks of T2DM were 3.37 (95% CI: 1.05-10.86, P =0.042) and 4.71 (95% CI: 1.71-12.99, P =0.003), respectively, in the low-CK-18 NAFLD and high-CK-18 NAFLD groups. Conclusions: Higher CK-18 level in ultrasound-diagnosed NAFLD patients is associated with higher risk of T2DM. We recommend screening for NAFLD using ultrasound in the first instance, with, if possible, CK-18 assay being subsequently used to screen individuals at higher risk of diabetes.

scholarly journals Decrease in Sleep Duration and Poor Sleep Quality over Time Is Associated with an Increased Risk of Incident Non-Alcoholic Fatty Liver Disease

2022 ◽  
Vol 12 (1) ◽  
pp. 92
Author(s):  
Yoo Jin Um ◽  
Yoosoo Chang ◽  
Hyun-Suk Jung ◽  
In Young Cho ◽  
Jun Ho Shin ◽  
...  
Keyword(s):  
Sleep Quality ◽  
Sleep Duration ◽  
Poor Sleep ◽  
Poor Sleep Quality ◽  
Alcoholic Fatty Liver ◽  
Increased Risk ◽  
Alcoholic Fatty Liver Disease ◽  
Good Sleep ◽  
Over Time

The impact of changes in sleep duration and sleep quality over time on the risk of non-alcoholic fatty liver disease (NAFLD) is not known. We investigated whether changes in sleep duration and in sleep quality between baseline and follow-up are associated with the risk of developing incident NAFLD. The cohort study included 86,530 Korean adults without NAFLD and with a low fibrosis score at baseline. The median follow-up was 3.6 years. Sleep duration and quality were assessed using the Pittsburgh Sleep Quality Index. Hepatic steatosis (HS) and liver fibrosis were assessed using ultrasonography and the fibrosis-4 index (FIB-4). Cox proportional hazard models were used to determine hazard ratios (HRs) and 95% confidence intervals (Cis). A total of 12,127 subjects with incident HS and 559 with incident HS plus intermediate/high FIB-4 was identified. Comparing the decrease in sleep duration of >1 h, with stable sleep duration, the multivariate-adjusted HR (95% CIs) for incident HS was 1.24 (1.15–1.35). The corresponding HRs for incident HS plus intermediate/high FIB-4 was 1.58 (1.10–2.29). Comparing persistently poor sleep quality with persistently good sleep quality, the multivariate-adjusted HR for incident HS was 1.13 (95% CI, 1.05–1.20). A decrease in sleep duration or poor sleep quality over time was associated with an increased risk of incident NAFLD, underscoring an important potential role for good sleep in preventing NAFLD risk.

NATURAL HISTORY OF CIRRHOSIS: CHANGING TRENDS IN ETIOLOGY OVER THE YEARS

2020 ◽  
Author(s):  
Ramazan Idilman ◽  
Merve Aydogan ◽  
Mehmet Berk Oruncu ◽  
Aysun Kartal ◽  
Atilla Halil Elhan ◽  
...  
Keyword(s):  
Natural History ◽  
Chronic Viral Hepatitis ◽  
Alcoholic Fatty Liver ◽  
Changing Trends ◽  
B Virus ◽  
Common Causes ◽  
History Of ◽  
Cirrhotic Patients ◽  
Alcoholic Fatty Liver Disease

Background and goals: The aims of the present study were to investigate the natural history of cirrhosis and to determine trends in the etiology of cirrhosis. Methods: Between January 2001 and January 2018, a total of 1341 patients had been diagnosed with cirrhosis were included. Results: A total of 898 cirrhotic patients, who were followed for at least six months were included into the analysis. The median age was 54 years. The median Child-Pugh and MELD scores were 7.5 and 11, respectively. Ascites (51%) was the most common causes of decompensation. Chronic viral hepatitis was the most frequent cause of cirrhosis (58%). Hepatitis B virus (HBV) infection was the main etiology (34%), followed by hepatitis C virus (HCV) infection (18%). Among 129 patients with cryptogenic cirrhosis (CC), 60 had metabolic abnormalities. If these 60 patients with CC were considered to have non-alcoholic fatty liver disease (NAFLD)-related cirrhosis, the proportion of NAFLD-related cirrhosis increased from 1.8% to 8.0%. At admission, 74 patients (8%) had been diagnosed with hepatocellular carcinoma (HCC). A new HCC developed in 80 patients during the follow-up period. The probability of developing HCC was 3.9% at 12 months. Logistic regression analysis showed that the development of HCC was significantly associated with older age (p<0.001), male gender (p<0.001), viral etiology (p=0.026) and baseline high aspartate aminotransferase level (p=0.01). Overall, 104 cirrhotic patients died. In conclusion: HBV and HCV remain the leading causes of etiology in cirrhosis and HCC. However, NAFLD-related cirrhosis is recognized is recognized as a growing burden.

Sign in / Sign up

Export Citation Format

Share Document